---
schema_version: "secwatch.filing_event.v1"
accession: "0001125345-25-000100"
form_type: "8-K"
ticker: "MGNX"
cik: "0001125345"
company_name: "MACROGENICS INC"
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T12:48:30.450000+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MacroGenics Q2 2025 net loss $36.3M; new CEO Eric Risser outlines strategic priorities

## Summary
- Cash, equivalents and marketables $176.5M as of June 30, 2025; cash runway through first half 2027.
- Total revenue $22.2M ($15.4M contract manufacturing, $6.9M collaboration vs. $10.8M year ago).
- Net loss improved to $36.3M ($0.57/share) from $55.7M ($0.89/share) in Q2 2024.
- Eric Risser named President and CEO, succeeding Scott Koenig who stepped down after 24 years.
- Received $70M upfront from Sagard Healthcare for ZYNYZ royalty purchase agreement.

## SEC filing metadata
- accession: 0001125345-25-000100
- form_type: 8-K
- ticker: MGNX
- cik: 0001125345
- company_name: MACROGENICS INC
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1125345/000112534525000100/0001125345-25-000100-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1125345/000112534525000100/mgnx-20250814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001125345-25-000100
- JSON: https://secwatch.observer/filing/0001125345-25-000100.json
- Plain text: https://secwatch.observer/filing/0001125345-25-000100.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.